Marker Therapeutics Inc (MRKR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Marker Therapeutics Inc (MRKR) has a cash flow conversion efficiency ratio of -0.102x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.40 Million) by net assets ($13.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Marker Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
Marker Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Marker Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Marker Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Marker Therapeutics Inc ranked by their cash flow conversion efficiency. Explore MRKR cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Euro Kapital Yatirim Ortakligi AS
IS:EUKYO
|
0.141x |
|
Mexco Energy Corporation
NYSE MKT:MXC
|
0.045x |
|
Dunelm Group PLC
LSE:DNLM
|
0.128x |
|
Sphere 3D Corp
NASDAQ:ANY
|
-0.186x |
|
Climeon AB (publ)
ST:CLIME-B
|
-0.061x |
|
Orgabio Holdings Bhd
KLSE:0252
|
0.122x |
|
Maniker F & G Co. Ltd
KQ:195500
|
0.043x |
|
ZECON Bhd
KLSE:7028
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Marker Therapeutics Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Marker Therapeutics Inc from 1999 to 2025. View MRKR stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.80 Million | $-12.01 Million | -0.715x | -21.67% |
| 2024-12-31 | $18.56 Million | $-10.91 Million | -0.588x | +49.75% |
| 2023-12-31 | $14.05 Million | $-16.44 Million | -1.170x | +14.98% |
| 2022-12-31 | $19.60 Million | $-26.97 Million | -1.376x | -121.87% |
| 2021-12-31 | $43.99 Million | $-27.28 Million | -0.620x | +15.35% |
| 2020-12-31 | $27.34 Million | $-20.03 Million | -0.733x | -76.66% |
| 2019-12-31 | $44.09 Million | $-18.28 Million | -0.415x | -69.97% |
| 2018-12-31 | $59.34 Million | $-14.48 Million | -0.244x | +89.42% |
| 2017-12-31 | $3.66 Million | $-8.44 Million | -2.307x | -119.17% |
| 2016-12-31 | $6.18 Million | $-6.51 Million | -1.053x | -617.66% |
| 2015-12-31 | $-21.36 Million | $-4.34 Million | 0.203x | -90.48% |
| 2014-12-31 | $-1.02 Million | $-2.19 Million | 2.137x | +2597.17% |
| 2013-12-31 | $-8.77 Million | $-694.58K | 0.079x | -71.32% |
| 2012-12-31 | $-5.67 Million | $-1.57 Million | 0.276x | -27.04% |
| 2011-12-31 | $-3.46 Million | $-1.31 Million | 0.379x | +33.91% |
| 2010-12-31 | $-3.27 Million | $-925.04K | 0.283x | -84.14% |
| 2009-12-31 | $-629.39K | $-1.12 Million | 1.782x | +654.23% |
| 2008-12-31 | $-3.02 Million | $-714.42K | 0.236x | -67.71% |
| 2007-12-31 | $-1.67 Million | $-1.23 Million | 0.732x | +85.14% |
| 2006-12-31 | $-3.00 Million | $-1.19 Million | 0.395x | -24.67% |
| 2005-12-31 | $-2.22 Million | $-1.16 Million | 0.525x | +5.38% |
| 2004-12-31 | $-2.44 Million | $-1.21 Million | 0.498x | -87.63% |
| 2003-12-31 | $-643.75K | $-2.59 Million | 4.026x | +233.30% |
| 2002-12-31 | $465.83K | $-1.41 Million | -3.020x | -292.90% |
| 2000-12-31 | $-561.95K | $-879.74K | 1.566x | -72.84% |
| 1999-12-31 | $-141.42K | $-815.18K | 5.764x | -- |
About Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-assoc… Read more